The price, $74 a share, represents a 38 percent premium to InterMune’s closing price on Friday and a 63 percent premium to the price on Aug. 12, before news reports that InterMune might be acquired.
The acquisition was announced during a flurry of pharmaceutical deals and attempted deals. About $87 billion in pharmaceutical acquisitions were made in the first half of this year, eclipsing the total for all of 2013, according to Evaluate, a research company. The total for the first half does not include the $54 billion acquisition of Shire by AbbVie, which was formally announced in July.
InterMune, based in Brisbane, Calif., has one product on the market: a drug called pirfenidone to treat idiopathic pulmonary fibrosis, a fatal scarring of the lungs.
Sales of Esbriet were $35.7 million in the second quarter, but some analysts expect annual revenues to eventually exceed $1 billion.
for the rest of the article, go to: http://dealbook.nytimes.com/2014/08/24/roche-to-buy-drug-maker-intermune-for-8-3-billion/?_php=true&_type=blogs&_php=true&_type=blogs&_r=1